Whitehawk Shares Rise After Forming Collaboration With Tempus AI to Advance Oncology Research
MT Newswires Live
Oct 16
Whitehawk Therapeutics (WHWK) shares were sharply higher Thursday after the company formed a multi-year collaboration with Tempus AI (TEM) to leverage Tempus' real-world dataset to advance biomarker-driven research and further Whitehawk Therapeutics' oncology pipeline, Tempus said.
The collaboration will focus on Whitehawk Therapeutics' antibody drug conjugates portfolio, which includes three assets designed to target proteins that are broadly expressed in high-potential cancer indications, such as lung and gynecological cancers, the company said.
Shares of Tempus AI and Whitehawk were up 5.3% and 54.7%, respectively, in early trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.